Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and Co's quarterly accounts payable & accrued expense
declined
from Dec. 2025 (CHF18,138 Mil) to Mar. 2026 (CHF17,774 Mil) but then
increased
from Mar. 2026 (CHF17,774 Mil) to Jun. 2026 (CHF21,768 Mil).
Eli Lilly and Co's annual accounts payable & accrued expense
declined
from Dec. 2023 (CHF13,367 Mil) to Dec. 2024 (CHF13,167 Mil) but then
increased
from Dec. 2024 (CHF13,167 Mil) to Dec. 2025 (CHF18,138 Mil).
Eli Lilly and Co Accounts Payable & Accrued Expense Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co Accounts Payable & Accrued Expense Chart
Eli Lilly and Co Accounts Payable & Accrued Expense Calculation
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
What does a Accounts Payable & Accrued Expense of CHF21,768 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Accounts Payable & Accrued Expense of CHF21,768 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Accounts Payable & Accrued Expense too high?
Eli Lilly and Co's current Accounts Payable & Accrued Expense is CHF21,768 Mil. Overall, Eli Lilly and Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Accounts Payable & Accrued Expense compare to JNJ and ABBV?
Eli Lilly and Co's Accounts Payable & Accrued Expense of CHF21,768 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Accounts Payable & Accrued Expense is CHF21,768 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,239.14, compared to a current price of CHF1,010.00 — trading 18.5% below its estimated fair value. The current Accounts Payable & Accrued Expense is CHF21,768 Mil. Eli Lilly and Co's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Accounts Payable & Accrued Expense is CHF21,768 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF1,010.00 is trading 18.5% below its estimated GF Value™ of CHF1,239.14.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Accounts Payable & Accrued Expense: CHF21,768 Mil
GF Value™: CHF1,239.14 vs. price of CHF1,010.00 (18.5% below fair value)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
92GF Score
Get the complete analysis for XSWX:LLY
Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
